California is currently home to 5615 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Recruiting
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: University of California, San Francisco (UCSF), San Francisco, California
Conditions: Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
A Study of Sovilnesib in Subjects with Ovarian Cancer
Recruiting
This is a randomized, phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of sovilnesib at different dose levels to establish the Recommended Phase 2 Dose (RP2D) of sovilnesib in subjects with high grade serous ovarian cancer (HGSOC).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: UCLA, Los Angeles, California
Conditions: High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Recruiting
This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period of 52 weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/16/2024
Locations: Reviva site, Garden Grove, California
Conditions: Schizophrenia
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
Recruiting
This is a 2 stage multi-center study designed to evaluate the efficacy of the combination of alpelisib and fulvestrant in patients with PIK3CA-mutated ER-positive endometrioid endometrial cancers by estimating the objective response rate (ORR). Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: City of Hope, Duarte, California
Conditions: Endometroid Endometrial Cancer
Avoid and Resist Strategies for Weight Management
Recruiting
The proposed randomized controlled trial tests two self-regulatory approaches to improve intentional weight loss and diet quality in individuals with overweight or obesity: (1) an environmental control strategy (AVOID) and (2) an impulse control training strategy (RESIST).
Gender:
ALL
Ages:
14 years and above
Trial Updated:
12/16/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Obesity, Overweight
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Recruiting
This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: City of Hope, Duarte, California
Conditions: Cervical Cancer
Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens
Recruiting
Women at risk for development of breast cancer and experiencing vasomotor menopausal symptoms (hot flashes) will be randomized to bazedoxifene (BZA) plus conjugated estrogens (CE) for 6 months versus a wait list control. Two risk factors for development of breast cancer will be studied pre-study and after 6 months: fibroglandular volume (FGV) on mammogram as assessed by Volpara software and proliferation by Ki-67 immunocytochemistry in benign breast tissue acquired by random periareolar fine nee... Read More
Gender:
FEMALE
Ages:
Between 45 years and 64 years
Trial Updated:
12/16/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Risk Reduction, Breast Cancer
NOninVasive Intracranial PrEssure from Transcranial DoppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Recruiting
This is an observational study in neurocritical care units at University of California San Francisco Medical Center (UCSFMC), Zuckerberg San Francisco General Hospital (ZSFGH), UC Davis, and Emory University. In this study, the investigators will primarily use the monitor mode of the Transcranial Doppler (TCD, non-invasive FDA approved device) to record cerebral blood flow velocity (CBFV) signals from the Middle Cerebral Artery and Internal Carotid Artery. TCD data and intracranial pressure (ICP... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: UC Davis, Davis, California
Conditions: Traumatic Brain Injury, Subarachnoid Hemorrhage, Intracerebral Hemorrhage, Liver Failure, Ischemic Stroke
Rare CFTR Mutation Cell Collection Protocol (RARE)
Recruiting
Over 1,900 mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein are implicated in causing Cystic Fibrosis (CF). Potential therapies that directly target defective CFTR are being evaluated in important clinical trials, but most target the most common CFTR mutation F508del. Many patients with rare CF mutations are not able to participate in those studies. The RARE study is specifically designed for people with CF caused by rare mutations. Eligible rare m... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/16/2024
Locations: Lucile S. Packard Children's Hospital, Palo Alto, California
Conditions: Cystic Fibrosis
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
Recruiting
This study will demonstrate the safety and effectiveness of the Edwards Lifesciences SAPIEN 3/SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve (THV) Systems in subjects with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted valve in the pulmonic position with a clinical indication for intervention.
Gender:
ALL
Ages:
All
Trial Updated:
12/16/2024
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
Recruiting
This phase II trial compares the effects, good and/or bad of abiraterone and prednisone or darolutamide alone in treating patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Androgens (male hormones) can cause the growth of prostate tumor cells. Abiraterone acetate lowers the amount of androgens made by the body. This may help stop the growth of prostate tumor cells that need androgen to grow. Daro... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Advanced Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Recruiting
This phase I trial tests the safety, tolerability and effectiveness of PLZ4-coated paclitacel-loaded micelles (PPM) in treating patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent) or that does not respond to treatment (refractory). PPM is a bladder cancer-specific nanoparticle that can specifically target and deliver treatment to the tumor cells in the bladder. PPM contains paclitaxel, which is a drug that kills tumor cells or keeps them... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8